The Uscom Ltd (ASX: UCM) share price tumbled today after the company released its quarterly cash report, showing significant falls across every major category.

The Uscom share price was down 6% at the close of trade today, at 15.5 cents per share.

A quick take on Uscom

Uscom is a medical technology company engaged in developing, designing, manufacturing, and marketing premium non-invasive cardiovascular and pulmonary medical devices.

The company's geographical segment includes Australia, Asia, the Americas, Europe, and other regions. It generates maximum revenue from Asia.

The company offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function; BP+; a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart; and SpiroSonic, a pulmonary function testing device based on multi-path ultrasound technology.

Uscom's financial woes

For the third quarter of FY21, Uscom reported cash receipts of $0.89 million for the period, which is down 53% from $1.91 million in the preceding quarter, and at $4.2 million year-to-date with Q4 trading still ahead.

Uscom's sales revenue was $0.78 million, down 20% from $0.98 million in the previous quarter. This follows its record growth of cash receipts of 149% and sales revenue of 125% reported in the prior Q2.

For the current quarter, Uscom's global entity reported a net operating cash outflow of $0.25 million, while for Q2, cash flow was positive at $0.3 million. Uscom remains cash flow positive for the YTD with $2.03 million cash on hand on 31 March.

What did management say?

Uscom executive chair Professor Rob Phillips said that the future looked a lot brighter for the company.

Q3 sales and receipts remain strong but down due to the impact of the Chinese New Year, effecting China activity for 6 weeks, while both European and US activities remained constrained by the pandemic. Hungary has effectively been closed for the quarter and our US team are still unable to attend hospitals and clinics.

However, we remain cash flow positive for the YTD, supported by strong China sales. Going forward, management noted the 18.3% GDP growth in China for the March quarter and look forward to this growth converting into health spending.

Uscom share price snapshot

The Uscom share price has been tumbling for some time. It's down 11% over the past month, 3% since 2021 began and 26% over the past 12 months. 

The post The Uscom (ASX:UCM) share price plunged 6% today. Here's why appeared first on The Motley Fool Australia.

The spread of coronavirus has infected global share markets with the contagion of fear. The S&P/ASX 200 Index (INDEXASX: XJO) has fallen more than 10% in the last fortnight as investors flee to safe havens.

This week, the Reserve Bank of Australia cut the cash rate to an all-time low of 0.5% in an effort to stimulate the slowing economy. 

But it's not all doom and gloom. Some ASX shares are fighting coronavirus with demand for their products accelerating along with the spread of the virus. So, let's take a look at the ASX shares that are racing ahead of the tragic epidemic. 

Zoono Group Ltd (ASX: ZNO)

The Zoono share price has risen more than 230% this year at the time of writing as demand for its sanitiser products has increased. The company has advised that it is extremely well-positioned to be part of the solution to coronavirus. Late last week, Zoono reported that test results showed the technology used in its hand sanitiser is 99.99% effective against coronavirus. 

In early January, Zoono ramped up production of key active ingredients in its sanitisers. This was a prescient decision as demand for products has been strong. Product orders in excess of NZ$1 million were received in the last two weeks of January, predominantly from China and Hong Kong. Online sales have increased significantly and forward orders and product enquiries are increasingly strong. 

Zoono entered into a distribution agreement with Eagle Health Holdings Ltd (ASX: EHH) in late February for the distribution of co-branded products and offline retail sales in China. Eagle will import Zoono's products in bulk to its facility in Xiamen, China, where they will be packaged and labelled, and then distributed. 

Eagle has more than 300 stores throughout China plus 271 distribution partners which place Eagle's products into more than 30,000 outlets across the country. An initial order for Zoono product valued at NZ$400,000 has been placed. Minimum purchase volumes under the agreement are NZ$1.5 million in the first 12 months, NZ$2.3 million in year two, and NZ$3.1 million in year three. 

Food Revolution Group Ltd (ASX: FOD)

Shares in Food Revolution Group are up more than 50% since mid-February following the announcement the company would be entering the hand sanitiser business. The coronavirus outbreak has created a shortage of hand-sanitiser in the Asia Pacific region with Food Revolution Group looking to meet unmet demand. 

Food Revolution Group's hand sanitiser has been formulated under the newly-formed 'Sanicare' brand and will be produced at the company's Mill Park facility in Melbourne. The facility underwent an upgrade in December including the construction of a self-contained clean room and laboratory.

Food Revolution Group has formulated and sourced the ingredients for its alcohol-based hand sanitiser and commenced production in February. 

The company received its first order for the hand sanitiser, valued at $2 million, in late February. The order is expected to be fulfilled and cash received in 4 weeks. 

Uscom Ltd (ASX: UCM)

Uscom shares are up more than 200% since the end of January following a material increase in orders for its USCOM 1A haemodynamic monitor from China. The National Health Commission of the People's Republic of China Coronavirus Protocol advocates haemodynamic monitoring for severe coronavirus cases. 

The first Chinese hospital to be equipped with an USCOM 1A specifically for the management of coronavirus was commissioned in late January. Uscom is planning to increase manufacturing output by approximately 121% on 10-year average outputs to meet anticipated demand in the second half. Unit orders for the first five weeks of 2020 were up 124% compared to the first full two months of 2019. 

Executive Chairman Rob Phillips said, "the USCOM 1A is a specialised technology developed to simplify diagnosis and management of infectious diseases and is now being implemented widely in China to save the lives of the most seriously ill patients. This epidemic is forcing our technology from the hands of a small number of infectious disease experts into the hands of physicians dealing day to day with tens of thousands of patients with deadly infections."

Aeris Environmental Ltd (ASX: AEI)

Aeris Environmental shares are up nearly 90% since early February with its disinfectant listed by the Singapore National Environment Agency on the list of general disinfectants effective against the coronavirus. The company's proprietary hospital-grade disinfectant, Aeris Active, provides broad-spectrum viricidal, bactericidal, and fungicidal efficacy, and affords long-term protection of at-risk surfaces. 

Aeris is currently scaling up production and redirecting its near term manufacturing capacity to multiple Australian manufacturing sites. This will support the needs of customers and growing demand in China and the Asia Pacific region. 

Holista Colltech Limited (ASX: HCT)

Shares in Holista Colltech have increased over 70% since the end of January as demand for its sanitisers increases. In February, Holista announced it would ship a further 90,000 NatShield sanitisers just days after the first 60,000 units sold out. Fresh orders were received from Malaysia, Australia, and other parts of Asia amidst rising concerns over the spread of coronavirus. 

NatShield sanitisers contain Path-Away, a plant-based active ingredient approved for use by Malaysia's Ministry of Health and Food and Safety Authority and Environmental Protection Authority of New Zealand.

Holista has also accelerated development of a nasal balm version of its sanitiser featuring Path-Away. It intends to file a global patent for the product in March and make the product available to the market by July. 

Biotron Limited (ASX: BIT)

Biotron shares are up more than 60% since the end of January as the company tests its compounds against the current strain of coronavirus, COVID-19. The company develops anti-viral drugs and has compounds that have shown good activity against several strains of coronavirus. Testing is focused on assessing whether Biotron's compounds can inhibit growth in COVID-19. 

Biotron scientists have identified and characterised a protein found in all coronaviruses and have shown that by targeting this protein, the virus could be inactivated. Given Biotron's expertise in antiviral drug development, an assessment of the activity of the company's compounds against COVID-19 is progressing as quickly as possible. 

The post These ASX shares are fighting the spread of coronavirus appeared first on The Motley Fool Australia.

The Uscom Ltd (ASX: UCM) share price rocketed higher today following the announcement that the Chinese government has recommended one of its products for use in treating coronavirus.

After surging as much as 38.7% in afternoon trade, Uscom shares closed the day 29.03% higher at $0.40 per share.

Uscom's business

Uscom manufactures non-invasive cardiovascular and pulmonary medical devices. Its cornerstone product is the Uscom 1A advanced hemodynamic monitor which is used to measure cardiovascular function.

The company also manufactures and markets a blood pressure measuring device and a pulmonary function testing device. Uscom reports it has a strong product pipeline projecting well into the next 10 years. 

Uscom's 1H20 results

Uscom delivered its half-year results today reporting a 35% decline in revenue which fell to $0.96 million in the first half. Revenue was delayed as the company restructured its China distribution operations. A new subsidiary was commissioned in Beijing with the first imports of devices into China occurring late in the half. Sales were also delayed by the lengthy approval process by China's National Medical Products Administration (NMPA). 

Approval was received at the end of the half, while the China subsidiary revised previous distribution contracts increasing both margins and volume. A rapid increase in cash receipts followed the close of the first half with a $0.52 million increase in cash on hand in the first eight weeks of the second half. 

It was a slow half in Europe as regulatory approvals have been slow to be released, resulting in reduced international sales. As the approvals are received, sales opportunities are expected to increase.

In the US, Uscom contracted an additional 28 sales personnel to sell devices to over 80% of the nation's geography. This significant increase in reach into the largest medical device market in the world has increased sales leads, with sales expected to follow.

The significant restructuring in distribution across all three major markets is in preparation for regulatory approval for new products BP+ and SpiroSonic.

Uscom Executive Chairman Rob Phillips said, "operationally our significant restructure of sales and marketing strategies across China, Europe, and the US is beginning to generate results and significant incoming cash. . . .  we are shifting manufacturing into top gear to meet anticipated demand."

Chinese Government recommendation

Uscom also announced today that the Chinese Government has recommended Uscom 1A for treating severe cases of coronavirus and is installing devices into Chinese hospitals.

Uscom Executive Chairman Rob Phillips said, "The Chinese National Health and Medical Commission publishing national coronavirus guidelines specifically and generally recommending Uscom 1A technology to treat adults and children with the most severe cases of the most significant global health epidemic in 20 years. This government recognition for the years of science to develop our Uscom 1A demonstrates we are changing global practice."

The post Why this small-cap ASX healthcare share surged 39% higher today appeared first on The Motley Fool Australia.